Browsing by Author "Turan T."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men
    (2013) Bozkurt O.; Bolat D.; Demir O.; Ucer O.; Şahin A.; Ozcift B.; Pektaş A.; Turan T.; Gümüş B.H.; Can E.; Bolukbasi A.; Erol H.; Esen A.
    The aim of this study was to evaluate the relationship between lower urinary tract symptoms (LUTSs), erectile dysfunction (ED) and symptomatic late-onset hypogonadism (SLOH) in ageing men in the Aegean region of Turkey. Five hundred consecutive patients >40 years old who had been in a steady sexual relationship for the past 6 months and were admitted to one of six urology clinics were included in the study. Serum prostate-specific antigen and testosterone levels and urinary flow rates were measured. All patients filled out the International Prostate Symptom Score and Quality of Life (IPSS-QoL), International Index of Erectile Function (IIEF) and Aging Males' Symptoms (AMS) scale forms. Of the patients, 23.9% had mild LUTSs, 53.3% had moderate LUTSs and 22.8% had severe LUTSs. The total testosterone level did not differ between groups. Additionally, 69.6% had ED. The presence of impotence increased with increasing LUTS severity. Symptomatic late-onset hypogonadism (AMS >27) was observed in 71.2% of the patients. The prevalence of severe hypogonadism symptoms increased with the IPSS scores. A correlation analysis revealed that all three questionnaire scores were significantly correlated. In conclusion, LUTS severity is an age-independent risk factor for ED and SLOH. LUTS severity and SLOH symptoms appear to have a strong link that requires etiological and biological clarification in future studies. © 2013 AJA, SIMM & SJTU. All rights reserved.
  • No Thumbnail Available
    Item
    Multicenter analysis of gestational trophoblastic neoplasia in Turkey
    (Asian Pacific Organization for Cancer Prevention, 2014) Ozalp S.S.; Telli E.; Oge T.; Tulunay G.; Boran N.; Turan T.; Yenen M.; Kurdoglu Z.; Ozler A.; Yuce K.; Ulker V.; Arvas M.; Demirkiran F.; Bese T.; Tokgozoglu N.; Onan A.; Sanci M.; Gokcu M.; Tosun G.; Dikmen Y.; Ozsaran A.; Terek M.C.; Akman L.; Yetimalar H.; Kilic D.S.; Gungor T.; Ozgu E.; Yildiz Y.; Kokcu A.; Kefeli M.; Kuruoglu S.; Yuksel H.; Guvenal T.; Hasdemir P.S.; Ozcelik B.; Serin S.; Dolanbay M.; Arioz D.T.; Tuncer N.; Bozkaya H.; Guven S.; Kulaksiz D.; Varol F.; Yanik A.; Ogurlu G.; Simsek T.; Toptas T.; Dogan S.; Camuzoglu H.; Api M.; Guzin K.; Caliskan E.; Doger E.; Cakmak B.; Ilhan T.T.
    Background: To evaluate the incidence, diagnosis and management of GTN among 28 centers in Turkey. Materials and Methods: A retrospective study was designed to include GTN patients attending 28 centers in the 10-year period between January 2003 and May 2013. Demographical characteristics of the patients, histopathological diagnosis, the International Federation of Gynecology and Obstetrics (FIGO) anatomical and prognostic scores, use of single-agent and multi-agent chemotherapy, surgical interventions and prognosis were evaluated. Results: From 2003-2013, there were 1,173,235 deliveries and 456 GTN cases at the 28 centers. The incidence was calculated to be 0.38 per 1,000 deliveries. According to the evaluated data of 364 patients, the median age at diagnosis was 31 years (range, 15-59 years). A histopathological diagnosis was present for 45.1% of the patients, and invasive mole, choriocarcinoma and PSTTs were diagnosed in 22.3% (n=81), 18.1% (n=66) and 4.7% (n=17) of the patients, respectively. Regarding final prognosis, 352 (96.7%) of the patients had remission, and 7 (1.9%) had persistence, whereas the disease was mortal for 5 (1.4%) of the patients. Conclusions: Because of the differences between countries, it is important to provide national registration systems and special clinics for the accurate diagnosis and treatment of GTN.